Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2008

01-07-2008 | Case Report

Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review

Authors: Makoto Murata, Yuichi Ishikawa, Haruhiko Ohashi, Seitaro Terakura, Kazutaka Ozeki, Hitoshi Kiyoi, Tomoki Naoe

Published in: International Journal of Hematology | Issue 1/2008

Login to get access

Abstract

A 49-year-old male developed recurrent acute myeloid leukemia 27 months after allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-identical brother. The immunophenotype of the blastic cell population was incompatible with that of the pre-transplant blast cells; a mutation in C/EBPA gene was found in the pre-transplant blast cells that was not present in the post-transplant blast cells, and short tandem repeat analysis of marrow cells, which included 71% blasts, showed complete donor chimera. Thus, this recipient developed donor cell leukemia (DCL). The donor was healthy when DCL developed in the recipient as well as before donation of the peripheral blood stem cells. Only five cases of DCL after PBSCT have been reported in the literature. As a mechanism for the development of DCL, a vigorous proliferative demand on the donor cells, which often correlates with a higher likelihood of replication error or mutation, has been proposed. Peripheral blood stem cells might have an advantage in that they are associated with a low incidence of DCL development because PBSCT recipients receive a higher total cell dose than recipients of bone marrow or cord blood cells.
Literature
1.
Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1971;1:251–5.CrossRefPubMed
2.
Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321:784–9.CrossRefPubMed
3.
Cooley LD, Sears DA, Udden MM, Harrison WR, Baker KR. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol. 2000;63:46–53.CrossRefPubMed
4.
Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, et al. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 2001;28:705–7.CrossRefPubMed
5.
Lawler M, Locasciulli A, Longoni D, Schiro R, McCann SR. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant. 2002;29:453–6. Erratum in: Bone Marrow Transplant. 2002;29:805.CrossRefPubMed
6.
Brunstein CG, Hirsch BA, Hammerschmidt D, McGlennen RC, Nguyen PL, Verfaillie CM. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2002;29:999–1003.CrossRefPubMed
7.
Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation—a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005;90:969–75.PubMed
8.
Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA, et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:511–7.CrossRefPubMed
9.
Matsunaga T, Murase K, Yoshida M, Fujimi A, Iyama S, Kuribayashi K, et al. Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol. 2005;79:294–8.CrossRefPubMed
10.
Fraser CJ, Hirsch BA, Dayton V, Creer MH, Neglia JP, Wagner JE, et al. First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood. 2005;106:4377–80.CrossRefPubMedPubMedCentral
11.
Ando T, Yujiri T, Mitani N, Takeuchi H, Nomiyama J, Suguchi M, et al. Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation. Leukemia. 2006;20:744–5.CrossRefPubMed
12.
Mitsui H, Nakazawa T, Tanimura A, Karasuno T, Hiraoka A. Donor cell-derived chronic myeloproliferative disease with t(7;11)(p15;p15) after cord blood transplantation in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2007;86:192–5.CrossRefPubMed
13.
Hamaki T, Kajiwara K, Kami M, Murashige N, Funaki M, Harima A, et al. Donor cell-derived acute monoblastic leukemia involving MLL gene translocation in an adult patient who received umbilical cord blood transplantation. Bone Marrow Transplant. 2008;41:91–2.CrossRefPubMed
14.
Cetin Z, Tezcan G, Karauzum SB, Kupesiz A, Manguoglu AE, Yesilipek A, et al. Donor cell-derived acute myeloblastic leukemia after allogeneic peripheral blood hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2006;28:763–7.CrossRefPubMed
15.
Kessinger A, Smith DM, Strandjord SE, Landmark JD, Dooley DC, Law P, et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant. 1989;4:643–6.PubMed
16.
Kiyoi H, Naoe T. Biology, clinical relevance, and moleculary targeted therapy in acute leukemia with FLT3 mutations. Int J Hematol. 2006;83:301–8.CrossRefPubMed
17.
Kiyoi H, Yamaji S, Kojima, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia. 2007;21:574–6.CrossRefPubMed
18.
Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624–33.CrossRefPubMed
19.
Ohashi H, Kato C, Fukami S, Saito H, Hamaguchi M. Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases. Am J Hematol. 2005;79:142–6.CrossRefPubMed
20.
Flynn CM, Kaufman DS. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood. 2007;109:2688–92.PubMed
21.
Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351:178–81.CrossRefPubMed
22.
Metcalfe JA, Parkhill J, Campbell L, Stacey M, Biggs P, Byrd PJ, et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet. 1996;13:350–3.CrossRefPubMed
23.
Niederwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D, et al. Inadvertent transmission of a donor’s acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med. 1990;322:1794–6.CrossRefPubMed
24.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.CrossRefPubMed
25.
Huntly BJP, Gilliland DG. Leukemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311–21.CrossRefPubMed
26.
Li Z, Li L. Understanding hematopoietic stem-cell microenvironments. Trends Biochem Sci. 2006;31:589–95.CrossRefPubMed
27.
Naoe T, Kiyoi H, Yamanaka K, Naito K, Yamada K. A case of cALL relapse after allogeneic BMT: recurrence of recipient cell origin, initially determined as being that of donor cell origin by sex chromosome analysis. Br J Haematol. 1989;73:420–2.CrossRefPubMed
Metadata
Title
Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review
Authors
Makoto Murata
Yuichi Ishikawa
Haruhiko Ohashi
Seitaro Terakura
Kazutaka Ozeki
Hitoshi Kiyoi
Tomoki Naoe
Publication date
01-07-2008
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0094-3

Other articles of this Issue 1/2008

International Journal of Hematology 1/2008 Go to the issue

Original Article

Expression of green fluorescent protein under the regulation of human locus control region elements HS2 and HS3 in transgenic mice

Letter to the Editor

All-trans-retinoic acid as a possible cause of acute pancreatitis even in the absence of hypertriglyceridemia

Letter to the Editor

Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation

Case Report

Epstein–Barr virus-associated T-cell lymphoma in an adult patient: prominent infiltrates within the liver portal area revealed by autopsy

Original Article

Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

Original Article

Periostin and bone marrow fibrosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits